Diabetes Type 1 TrialNet: Clinical Centers

描述（由申请人提供） 1型糖尿病在美国影响超过一百万人 以及世界各地更多的人。1型糖尿病是由遗传易感性 由于免疫介导的胰腺破坏， 胰岛分泌胰岛素的β细胞。糖尿病的临床症状 代表β细胞功能慢性进行性下降的终点 并且当大多数β细胞已经丢失时发生。一级 1型糖尿病患者的亲属有10倍的可能性 比一般人更容易得这种病。这种疾病，可以开始 在任何年龄，典型地开始于童年或青年。的 目前1型糖尿病的治疗方法，包括早期使用胰岛素， 严格的饮食干预和频繁的血糖监测，当 正确实施，可以延迟或预防可怕的长期并发症 糖尿病（即失明、肾衰竭和截肢）。但正当 糖尿病治疗是相当困难的，昂贵的，非常侵入性， 那个糖尿病患者吗的生活方式。糖尿病也是影响健康的一个主要因素 护理费用。1型糖尿病是什么？到目前为止，一些免疫 在遗传易感个体中尝试了干预措施， 成功其他审判试图在审判过程的早期进行干预。 1型糖尿病，以保持β细胞功能。这些免疫 干预措施同样失败。因此，识别 无论是预防疾病还是减缓其进展， 护理成本节约和减少与糖尿病有关的并发症， 在没有患病方面的巨大个人储蓄。我们的长期 1型糖尿病的治疗方法有哪些？ 创新的基于免疫的疗法，旨在防止发展的 遗传易感个体的疾病。这一目标 为了实现这一目标并响应RFA， 的DPT-1协议和TrialNet，一个增强的网络， 开发和测试创新干预措施，以预防或减缓疾病的进展 1型糖尿病其中一种创新的方法是减缓1型糖尿病的进展， 糖尿病是我们提出的试点方案，“噻唑烷二酮类保护C肽 1型糖尿病的发病率“这项工作是创新的，因为它利用了一种药物， 已经被广泛用于治疗 也是一种免疫调节剂。我们的中心有 经验，人员，并获得适当的病人是一个 成功的TrialNet成员，并能够成功地完成我们的 拟议的试点协议或TrialNet可能提出的其他协议。

DESCRIPTION (provided by applicant) Type 1 diabetes affects more than one million individuals in the United States and many more worldwide. Type 1 diabetes arises in genetically predisposed individuals as a consequence of immune-mediated destruction of the pancreatic islet insulin-secreting beta-cells. The onset of clinical symptoms of diabetes represents the endpoint of a chronic progressive decline in beta-cell function and occurs when the majority of beta-cells have been lost. First-degree relatives of individuals with Type 1 diabetes are ten-fold more likely to develop the disease than the general population. The disease, which can begin at any age, characteristically begins in childhood or in young adults. The present treatment for Type 1 diabetes, which includes the early use of insulin, rigid dietary intervention, and frequent blood glucose monitoring, when implemented properly, can delay or prevent the horrible long-term complications of diabetes (i.e. blindness, renal failure, and amputation). However, proper diabetes treatment is quite difficult to do, expensive, and very invasive to the diabetic patient?s lifestyle. Diabetes is also a major factor in health care costs. Is it possible to prevent Type 1 diabetes? To date, several immune interventions have been tried in genetically susceptible individuals without success. Other trials have been attempted to intervene early in the course of Type 1 diabetes, in order to preserve beta-cell function. These immune interventions have likewise failed. Thus, the identification of agents that either prevent the disease or slow its progression would result in major health care cost savings and reduce complications related to diabetes in addition to the huge individual savings in terms of not having the disease. Our long-term goal is to prevent the development of Type 1 diabetes through the use of innovative immune-based therapies designed to prevent the development of the disease in genetically predisposed individuals. The objectives of this application, in pursuit of that goal and in response to the RFA, is completion of the DPT-1 protocol and the development of TrialNet, an enhanced network to develop and test innovative interventions to prevent or slow the progression of Type 1 diabetes. One such innovative approach to slow the progression of Type 1 diabetes is our proposed pilot protocol, "Thiazolidinediones Preserve C-Peptide in Type 1 Diabetes." The proposed work is innovative because it utilizes a drug that has a proven safety profile and is already widely used for the treatment of Type 2 diabetes but also is an immune modulator. Our Center has the experience, the personnel, and access to the appropriate patients to be a successful member of TrialNet and to be able to successfully complete our proposed pilot protocol or others that TrialNet may bring forward.